By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Acyclovir

Acyclovir

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|614 words

Acyclovir Drug Profile

What is Acyclovir?

Acyclovir is an antiviral medication that belongs to the class of drugs known as nucleoside analogues. It is primarily used to treat infections caused by herpes viruses, including genital herpes, cold sores, shingles, and chickenpox. Acyclovir was one of the first effective antiviral medications developed and remains a cornerstone treatment for herpes virus infections.

Uses

Acyclovir is approved for several viral infections:

  • Genital herpes: Both initial outbreaks and recurrent episodes, as well as suppressive therapy to reduce frequency of outbreaks
  • Cold sores (oral herpes): Treatment of herpes simplex virus infections around the mouth and lips
  • Shingles (herpes zoster): Treatment of the painful rash caused by reactivation of the varicella-zoster virus
  • Chickenpox (varicella): Treatment in children and adults, particularly those at higher risk for complications
  • Herpes simplex encephalitis: Serious brain infection caused by herpes simplex virus

How it works

Acyclovir works by mimicking one of the building blocks that viruses need to replicate their genetic material. Once inside virus-infected cells, acyclovir is converted to its active form and interferes with the virus’s ability to copy itself. This stops the virus from spreading to new cells and helps the body’s immune system control the infection more effectively.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Dizziness
  • Fatigue
  • Skin rash or itching
  • Pain or irritation at injection site (IV form)
  • Abdominal pain

Serious side effects that require immediate medical attention:

  • Kidney problems, including decreased urination or blood in urine
  • Severe allergic reactions with difficulty breathing or swallowing
  • Neurological effects such as confusion, hallucinations, or seizures
  • Severe skin reactions or widespread rash
  • Signs of thrombotic thrombocytopenic purpura (unusual bruising or bleeding)

Warnings and precautions

Several important safety considerations apply to acyclovir use:

  • Kidney function: Patients with kidney disease require dose adjustments, and adequate hydration is essential to prevent kidney damage, especially with IV administration
  • Pregnancy and breastfeeding: Generally considered safe during pregnancy (Category B) when benefits outweigh risks, and small amounts pass into breast milk
  • Elderly patients: May be at higher risk for kidney problems and neurological side effects, requiring careful monitoring and possible dose adjustments
  • Immunocompromised patients: While often prescribed for this population, these patients may require higher doses and longer treatment duration
  • Dehydration risk: Maintaining adequate fluid intake is crucial, particularly with oral and IV forms

Interactions

Acyclovir can interact with several medications:

  • Probenecid: Increases acyclovir levels in the blood by reducing kidney elimination
  • Nephrotoxic drugs (aminoglycosides, amphotericin B): May increase risk of kidney damage when used together
  • Mycophenolate mofetil: Both drugs may have increased concentrations when used concurrently
  • Theophylline: Acyclovir may increase theophylline levels, requiring monitoring
  • Zidovudine: May increase risk of drowsiness and fatigue
  • Cimetidine: May increase acyclovir levels by reducing kidney clearance
  • Tenofovir: Potential for increased kidney toxicity when used together
  • Varicella virus vaccine: Acyclovir may reduce vaccine effectiveness

Check interactions with the GMJ Interaction Checker

Dosage

Acyclovir dosages vary significantly based on the condition being treated, severity of infection, and patient factors. Typical adult dosages include:

  • Genital herpes (initial episode): 400 mg three times daily or 200 mg five times daily for 7-10 days
  • Genital herpes (recurrent episodes): 400 mg three times daily for 5 days
  • Suppressive therapy: 400 mg twice daily
  • Shingles: 800 mg five times daily for 7-10 days
  • Chickenpox: 800 mg four times daily for 5 days

Dosages must be adjusted for patients with kidney problems, and IV formulations have different dosing schedules. All dosing should be determined and monitored by a qualified healthcare provider based on individual patient needs and medical history.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Acyclovir." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/acyclovir/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

St John’s Wort

By
Prof. Giorgi Pkhakadze
02/06/2026

Atazanavir

By
Prof. Giorgi Pkhakadze
02/06/2026

Iron supplements

By
Prof. Giorgi Pkhakadze
02/06/2026

Moclobemide

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up